Unique recombinant APRIL antibody confers atheroprotection

A recent study reports that APRIL confers atheroprotection by binding to heparan sulfate chains of heparan-sulfate proteoglycan 2 (HSPG2), which limits the retention of low-density lipoproteins, accumulation of macrophages and formation of necrotic cores. In this study, they use AdipoGen’s specific anti-APRIL (mouse) antibody (Apry-1-1) that promotes the binding of APRIL to HSPGs to reduce experimental atherosclerosis. They also observe that serum levels of a specific form of human APRIL that binds to HSPGs (termed non-canonical APRIL), are associated with long-term cardiovascular mortality in patients with atherosclerosis [ref. 1].

anti-APRIL (mouse), mAb (rec.) (blocking) (Apry-1-1)

AdipoGen Life Sciences’ anti-APRIL (mouse), mAb (rec.) (blocking) (Apry-1-1) (Cat. No. AG-27B-0001) is a recombinant monoclonal antibody that recognizes mouse APRIL and works specifically in IP and Functional Application. The antibody inhibits mouse APRIL binding to BCMA and TACI. It is highly potent in blocking mouse APRIL in vitro and in vivo. In addition it promotes the binding of APRIL to HSPGs and confers atheroprotection. The antibody is available with or without preservatives.

References

1. Tsiantoulas D, Eslami M, Obermayer G, et al. APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans. Nature. 2021;597(7874):92-96.